An update on testosterone, HDL and cardiovascular risk in men

References

• Bhasin S, Cunningham GR, Hayes FJ et al. Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J. Clin. Endocrinol. Metabol. 95(6), 2536–2559 (2010).
   Google Scholar
• Haddad RM, Kennedy CC, Caples SM et al. Testosterone and cardiovascular risk in men: a systematic review and meta-analysis of randomized placebo-controlled trials. Mayo Clin. Proc. 82(1), 29–39 (2007). • Meta-Analysis Of 30 Randomized Trials That Concluded That Testosterone Therapy In Men With Androgen Deficiency Was Not Associated With Cardiovascular Events.
   Google Scholar
• Basaria S, Coviello AD, Travison TG et al. Adverse events associated with testosterone administration. N. Engl. J. Med. 363(2), 109–122 (2010). •• Randomized Controlled Trial That Was Stopped Early Due To Higher Cardiovascular Events In Elderly, Frail Men With A High Prevalence Of Chronic Disease.
   Google Scholar
• Wu FC, Von Eckardstein A. Androgens and coronary artery disease. Endocrine Rev. 24(2), 183–217 (2003).
   Google Scholar
• Malkin CJ, Pugh PJ, Morris PD, Asif S, Jones TH, Channer KS. Low serum testosterone and increased mortality in men with coronary heart disease. Heart 96(22), 1821–1825 (2010).
   Google Scholar
• Khaw KT, Dowsett M, Folkerd E et al. Endogenous testosterone and mortality due to all causes, cardiovascular disease, and cancer in men: European prospective investigation into cancer in Norfolk (EPIC-Norfolk) Prospective Population Study. Circulation 116(23), 2694–2701 (2007).
   Google Scholar
• Haring R, Volzke H, Steveling A et al. Low serum testosterone levels are associated with increased risk of mortality in a population-based cohort of men aged 20–79. Eur. Heart J. 31(12), 1494–1501 (2010).
   Google Scholar
• Laughlin GA, Barrett-Connor E, Bergstrom J. Low serum testosterone and mortality in older men. J. Clin. Endocrinol. Metabol. 93(1), 68–75 (2008).
   Google Scholar
• Tivesten A, Vandenput L, Labrie F et al. Low serum testosterone and estradiol predict mortality in elderly men. J. Clin. Endocrinol. Metabol. 94(7), 2482–2488 (2009).
   Google Scholar
• Araujo AB, Dixon JM, Suarez EA, Murad MH, Guey LT, Wittert GA. Clinical review: endogenous testosterone and mortality in men: a systematic review and meta-analysis. J. Clin. Endocrinol. Metabol. 96(10), 3007–3019 (2011).
   Google Scholar
• Barrett-Connor E, Khaw KT. Endogenous sex hormones and cardiovascular disease in men. A prospective population-based study. Circulation 78(3), 539–545 (1988).
   Google Scholar
• Ohlsson C, Barrett-Connor E, Bhasin S et al. High serum testosterone is associated with reduced risk of cardiovascular events in elderly men. The MrOS (Osteoporotic Fractures in Men) study in Sweden. J. Am. Coll. Cardiol. 58(16), 1674–1681 (2011).
   Google Scholar
• Yeap BB, Alfonso H, Chubb SA et al. In older men, higher plasma testosterone or dihydrotestosterone is an independent predictor for reduced incidence of stroke but not myocardial infarction. J. Clin. Endocrinol. Metabol. 99(12), 4565–4573 (2014).
   Google Scholar
• Smith GD, Ben-Shlomo Y, Beswick A, Yarnell J, Lightman S, Elwood P. Cortisol, testosterone, and coronary heart disease: prospective evidence from the Caerphilly study. Circulation 112(3), 332–340 (2005).
   Google Scholar
• Shores MM, Biggs ML, Arnold AM et al. Testosterone, dihydrotestosterone, and incident cardiovascular disease and mortality in the cardiovascular health study. J. Clin. Endocrinol. Metabol. 99(6), 2061–2068 (2014).
   Google Scholar
• Vikan T, Schirmer H, Njolstad I, Svartberg J. Endogenous sex hormones and the prospective association with cardiovascular disease and mortality in men: the Tromso Study. Eur. J. Endocrinol. 161(3), 435–442 (2009).
   Google Scholar
• Contoreggi CS, Blackman MR, Andres R et al. Plasma levels of estradiol, testosterone, and DHEAS do not predict risk of coronary artery disease in men. J. Androl. 11(5), 460–470 (1990).
   Google Scholar
• Phillips GB, Yano K, Stemmermann GN. Serum sex hormone levels and myocardial infarction in the Honolulu Heart Program. Pitfalls in prospective studies on sex hormones. J. Clin. Epidemiol. 41(12), 1151–1156 (1988).
   Google Scholar
• Brambilla DJ, O’donnell AB, Matsumoto AM, Mckinlay JB. Intraindividual variation in levels of serum testosterone and other reproductive and adrenal hormones in men. Clin. Endocrinol. 67(6), 853–862 (2007).
   Google Scholar
• Ruige JB, Mahmoud AM, De Bacquer D, Kaufman JM. Endogenous testosterone and cardiovascular disease in healthy men: a meta-analysis. Heart 97(11), 870–875 (2011).
   Google Scholar
• Sartorius G, Spasevska S, Idan A et al. Serum testosterone, dihydrotestosterone and estradiol concentrations in older men self-reporting very good health: the healthy man study. Clin. Endocrinol. 77(5), 755–763 (2012).
   Google Scholar
• Calof OM, Singh AB, Lee ML et al. Adverse events associated with testosterone replacement in middle-aged and older men: a meta-analysis of randomized, placebo-controlled trials. J. Gerontol. A Biol. Sci. Med. Sci. 60(11), 1451–1457 (2005).
   Google Scholar
• Fernandez-Balsells MM, Murad MH, Lane M et al. Clinical review 1: adverse effects of testosterone therapy in adult men: a systematic review and meta-analysis. J. Clin. Endocrinol. Metabol. 95(6), 2560–2575 (2010).
   Google Scholar
• Xu L, Freeman G, Cowling BJ, Schooling CM. Testosterone therapy and cardiovascular events among men: a systematic review and meta-analysis of placebo-controlled randomized trials. BMC Med. 11, 108 (2013).
   Google Scholar
• Corona G, Maseroli E, Rastrelli G et al. Cardiovascular risk associated with testosterone-boosting medications: a systematic review and meta-analysis. Exp. Opin. Drug Safety 13(10), 1327–1351 (2014).
   Google Scholar
• Muraleedharan V, Marsh H, Kapoor D, Channer KS, Jones TH. Testosterone deficiency is associated with increased risk of mortality and testosterone replacement improves survival in men with Type 2 diabetes. Eur. J. Endocrinol. 169(6), 725–733 (2013).
   Google Scholar
• Srinivas-Shankar U, Roberts SA, Connolly MJ et al. Effects of testosterone on muscle strength, physical function, body composition, and quality of life in intermediate-frail and frail elderly men: a randomized, double-blind, placebo-controlled study. J. Clin. Endocrinol. Metabol. 95(2), 639–650 (2010). •• Randomized Controlled Trial That Did Not Show Any Increased Cardiovascular Risk In Elderly Frail Men Receiving Testosterone Replacement Therapy.
   Google Scholar
• The New York Times Editorial Board. Overselling Testosterone, Dangerously. New York Times, 4th February (2014). www.nytimes.com/2014/02/05/opinion/oversellingtestosterone-dangerously.html
   Google Scholar
• La Puma J. Don’t ask your doctor about ‘Low T’. New York Times, 3rd February (2014). www.nytimes.com/2014/02/04/opinion/dont-ask-yourdoctor-about-low-t.html
   Google Scholar
• Vigen R, O’donnell CI, Baron AE et al. Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels. JAMA 310(17), 1829–1836 (2013). • Retrospective Cross-Sectional Study Of 8000 Male Veterans That Reported An Association Between Testosterone Replacement Therapy And Incident Myocardial Infarction, Stroke Or Death.
   Google Scholar
• Katz J, Nadelberg R. Deaths and cardiovascular events in men receiving testosterone. JAMA 311(9), 963 (2014).
   Google Scholar
• Finkle WD, Greenland S, Ridgeway GK et al. Increased risk of non-fatal myocardial infarction following testosterone therapy prescription in men. PloS One 9(1), e85805 (2014).
   Google Scholar
• Shores MM, Smith NL, Forsberg CW, Anawalt BD, Matsumoto AM. Testosterone treatment and mortality in men with low testosterone levels. J. Clin. Endocrinol. Metabol. 97(6), 2050–2058 (2012).
   Google Scholar
• Roth JA, Etzioni R, Waters TM et al. Economic return from the Women’s Health Initiative estrogen plus progestin clinical trial: a modeling study. Ann. Intern. Med. 160(9), 594–602 (2014).
   Google Scholar
• Snyder PJ, Ellenberg SS, Cunningham GR et al. The testosterone trials: seven coordinated trials of testosterone treatment in elderly men. Clin. Trials 11(3), 362–375 (2014). •• Randomized Trial Of Testosterone Therapy In Hypogonadal Men That Has Recently Been Completed And Results In Terms Of Coronary Artery Plaque Volume And Lipids Are Awaited.
   Google Scholar
• Haffner SM, Mykkanen L, Valdez RA, Katz MS. Relationship of sex hormones to lipids and lipoproteins in nondiabetic men. J. Clin. Endocrinol. Metabol. 77(6), 1610–1615 (1993).
   Google Scholar
• Agledahl I, Skjaerpe PA, Hansen JB, Svartberg J. Low serum testosterone in men is inversely associated with nonfasting serum triglycerides: the Tromso study. Nutr. Metab. Cardiovasc. Dis. 18(4), 256–262 (2008).
   Google Scholar
• Makinen JI, Perheentupa A, Irjala K et al. Endogenous testosterone and serum lipids in middle-aged men. Atherosclerosis 197(2), 688–693 (2008).
   Google Scholar
• Khaw KT, Barrett-Connor E. Endogenous sex hormones, high density lipoprotein cholesterol, and other lipoprotein fractions in men. Arterioscler. Thromb. 11(3), 489–494 (1991).
   Google Scholar
• Zmuda JM, Cauley JA, Kriska A, Glynn NW, Gutai JP, Kuller LH. Longitudinal relation between endogenous testosterone and cardiovascular disease risk factors in middle-aged men. A 13–year follow-up of former Multiple Risk Factor Intervention Trial participants. Am. J. Epidemiol. 146(8), 609–617 (1997).
   Google Scholar
• Van Pottelbergh I, Braeckman L, De Bacquer D, De Backer G, Kaufman JM. Differential contribution of testosterone and estradiol in the determination of cholesterol and lipoprotein profile in healthy middle-aged men. Atherosclerosis 166(1), 95–102 (2003).
   Google Scholar
• Vaidya D, Dobs A, Gapstur SM et al. The association of endogenous sex hormones with lipoprotein subfraction profile in the Multi-Ethnic Study of Atherosclerosis. Metabol. Clin. Exp. 57(6), 782–790 (2008).
   Google Scholar
• Haring R, Baumeister SE, Volzke H et al. Prospective association of low total testosterone concentrations with an adverse lipid profile and increased incident dyslipidemia. Eur. J. Cardiovasc. Prev. Rehabil. 18(1), 86–96 (2011).
   Google Scholar
• Canoy D, Barber TM, Pouta A et al. Serum sex hormone-binding globulin and testosterone in relation to cardiovascular disease risk factors in young men: a population-based study. Eur. J. Endocrinol. 170(6), 863–872 (2014).
   Google Scholar
• Haring R, Xanthakis V, Coviello A et al. Clinical correlates of sex steroids and gonadotropins in men over the late adulthood: the Framingham Heart Study. Int. J. Androl. 35(6), 775–782 (2012).
   Google Scholar
• Whitsel EA, Boyko EJ, Matsumoto AM, Anawalt BD, Siscovick DS. Intramuscular testosterone esters and plasma lipids in hypogonadal men: a meta-analysis. Am. J. Med. 111(4), 261–269 (2001).
   Google Scholar
• Isidori AM, Giannetta E, Greco EA et al. Effects of testosterone on body composition, bone metabolism and serum lipid profile in middle-aged men: a meta-analysis. Clin. Endocrinol. 63(3), 280–293 (2005).
   Google Scholar
• Shabsigh R, Katz M, Yan G, Makhsida N. Cardiovascular issues in hypogonadism and testosterone therapy. Am. J. Cardiol. 96(12B), M67–M72 (2005).
   Google Scholar
• Basaria S. Androgen abuse in athletes: detection and consequences. J. Clin. Endocrinol. Metabol. 95(4), 1533–1543 (2010).
   Google Scholar
• Rubinow KB, Vaisar T, Tang C, Matsumoto AM, Heinecke JW, Page ST. Testosterone replacement in hypogonadal men alters the HDL proteome but not HDL cholesterol efflux capacity. J. Lipid Res. 53(7), 1376–1383 (2012). • Testosterone Therapy In 23 Older, Hypogonadal Men Altered The Hdl Proteome But Did Not Lower Hdl-C Concentrations Or Change Cholesterol Efflux Capacity.
   Google Scholar
• Barter PJ, Caulfield M, Eriksson M et al. Effects of torcetrapib in patients at high risk for coronary events. N. Engl. J. Med. 357(21), 2109–2122 (2007).
   Google Scholar
• Rosenson RS, Brewer HB Jr., Chapman MJ et al. HDL measures, particle heterogeneity, proposed nomenclature, and relation to atherosclerotic cardiovascular events. Clin. Chem. 57(3), 392–410 (2011).
   Google Scholar
• Langer C, Gansz B, Goepfert C et al. Testosterone upregulates scavenger receptor BI and stimulates cholesterol efflux from macrophages. Biochem. Biophys. Res. Commun. 296(5), 1051–1057 (2002). • In vitro Study That Demonstrated That Testosterone Therapy Caused Increased Hdl(3)-Mediated Cholesterol Efflux From Human Macrophages.
   Google Scholar
• Rubinow KB, Page ST. Testosterone, HDL and cardiovascular risk in men: the jury is still out. Clin. Lipidol. 7(4), 363–365 (2012).
   Google Scholar
• De La Llera-Moya M, Drazul-Schrader D, Asztalos BF, Cuchel M, Rader DJ, Rothblat GH. The ability to promote efflux via ABCA1 determines the capacity of serum specimens with similar high-density lipoprotein cholesterol to remove cholesterol from macrophages. Arterioscler. Thromb. Vasc. Biol. 30(4), 796–801 (2010).
   Google Scholar